"Let the experiment be made on a low-value body."
It sounds like a line whispered in a dimly lit, 17th-century dissection theater. Or maybe a directive muttered in the halls of an ancient Roman tribunal. The original Latin phrase is fiat experimentum in corpore vili, and while it originated as a legal and scholastic maxim centuries ago, it remains one of the most chilling formulas for human progress ever written. Read more on a related topic: this related article.
Historically, it was a practical rule of thumb for early scientists, physicians, and legal scholars. The logic was simple. If you must test a risky medical procedure, an unproven drug, or a radical new social theory, don't risk a citizen of high standing. Use a body of little worth.
We like to think we've evolved past this tier-based view of human life. We haven't. The language just got cleaner. The old mindset that front-loads risk onto the vulnerable to insulate the powerful didn't vanish with the Enlightenment. It just moved into clinical trials, algorithmic testing, and corporate risk management. Further journalism by Bloomberg delves into similar perspectives on this issue.
The Dark History of the Worthless Body
The phrase fiat experimentum in corpore vili didn't pull itself out of thin air. It emerged from a deeply stratified European intellectual environment that inherited its social structures straight from Roman civil law. In ancient Rome, the legal system explicitly divided people by value—slaves, non-citizens, and citizens had fundamentally different rights under the law.
By the 16th and 17th centuries, as empirical science began to break away from pure philosophy, early modern researchers needed a way to justify the grislier aspects of their work. Thinkers like Francis Bacon were championing the scientific method, pushing for systematic observation and physical testing. But early medicine was incredibly dangerous. Dissections, vivisections, and untested remedies frequently resulted in agony or death.
To resolve the moral tension between the pursuit of knowledge and the destruction of life, institutions leaned heavily on the concept of the corpus vile—the worthless body.
Who filled this role?
- Condemned criminals: In many European medical hubs, executed prisoners were handed directly over to anatomists.
- The destitute: Dead bodies unclaimed from poorhouses or public hospitals became standard material for medical students.
- The marginalized: Living subjects drawn from the lowest rungs of society were frequently used to test early, volatile vaccines and treatments before they were deemed safe for the wealthy.
The core argument was entirely utilitarian. The advancement of knowledge benefits the collective whole, so the risk should be absorbed by those who supposedly contribute the least to that whole.
When Progress Demands a Scapegoat
This wasn't just a fringe practice; it was an open structural reality. Consider how the legendary 19th-century French physiologist Claude Bernard—often called the father of experimental medicine—wrestled with this exact concept. Bernard famously argued that it was a duty to perform experiments on humans, but with a strict caveat: you must never perform an experiment that might harm the subject, even if the result could highly benefit science.
Yet, the broader scientific apparatus rarely held to such high ethical standards. The history of medicine is littered with instances where the corpore vili mindset overrode basic human empathy.
Look at the development of modern gynecology. J. Marion Sims, celebrated for decades as a pioneer in the field, achieved his surgical breakthroughs by operating on enslaved Black women in the American South during the 1840s—without anesthesia. Their bodies were viewed by the medical and legal systems of the time as having zero social value, making them the ultimate canvas for experimental risk.
Similarly, the infamous Tuskegee Syphilis Study, which ran from 1932 to 1972, treated hundreds of poor Black sharecroppers as little more than laboratory tissue. Researchers watched the natural progression of the disease without offering penicillin, simply to collect data.
The institutions behind these studies didn't see themselves as monsters. They saw themselves as pragmatists following the same old Latin rule. They were sacrificing a low-value cohort for the greater good of the high-value populace.
The Modern Metamorphosis of Corporate Risk
You don't see the words fiat experimentum in corpore vili on the walls of modern laboratories, but the underlying machinery functions the same way. The modern equivalent lives in the geography of clinical trials and the rollouts of unproven tech.
Take global pharmaceutical pipelines. Developing a new drug is astronomical in cost and carries immense risk. Where do companies run their early, high-risk clinical trials? Increasingly, they outsource them to developing nations or economically depressed regions across the Global South.
The participants in these regions often lack robust healthcare options, meaning they accept the profound risks of experimental drugs just to get basic medical attention. If something goes wrong, the legal liabilities are lower, the media fallout is minimal, and the local regulatory frameworks are far more permissive. The corporate world has essentially digitized and globalized the corpus vile.
We see it in the tech sector, too. When major artificial intelligence platforms or automated systems need training on raw, toxic data, the trauma of filtering that content isn't absorbed by engineers in Silicon Valley. It's outsourced to low-wage workers in Kenya or the Philippines who review horrific digital imagery for pennies an hour. Their psychological well-being is treated as expendable to refine a product meant for affluent global consumers.
Moving Beyond the Logic of Expendability
Breaking out of this historical loop requires more than just signing boilerplate ethical consent forms. The issue isn't a lack of paperwork; it's the systemic distribution of risk.
If you want to know whether an industry, a scientific project, or a policy is ethical, you have to look at who bears the downside when things fail. True ethical progress means flattening the hierarchy of risk. It means designing systems where those who stand to profit the most from a breakthrough are also the ones willing to share the immediate vulnerabilities of its creation.
Until we actively audit our supply chains, our research methods, and our corporate rollouts for this ancient bias, we're just running a cleaner version of the same old medieval theater. The bodies change, but the cold logic remains.
